{"id":"NCT00645671","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery","officialTitle":"A Randomized Multicenter, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate Ophthalmic Ointment, 0.5% Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-03","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2008-03-28","resultsPosted":"2010-09-23","lastUpdate":"2015-03-24"},"enrollment":400,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ocular Inflammation"],"interventions":[{"type":"DRUG","name":"0.5% Loteprednol Etabonate Ophthalmic Ointment","otherNames":[]},{"type":"DRUG","name":"Vehicle of Loteprednol Etabonate Ophthalmic Ointment","otherNames":[]}],"arms":[{"label":"Loteprednol Etabonate","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment, 0.5% vs. vehicle for the treatment of inflammation following cataract surgery","primaryOutcome":{"measure":"Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.","timeFrame":"Postoperative Day 8 (Visit 5)","effectByArm":[{"arm":"Loteprednol Etabonate","deltaMin":48,"sd":null},{"arm":"Vehicle","deltaMin":27,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":201},"commonTop":["Anterior chamber inflammation","Photophobia","Eye pain","Iritis","Conjunctival hyperemia"]}}